The rapid spread of carbapenem-resistant (nonsusceptible) Enterobacteriaceae has become a great challenge for physicians \[[@CIT0001]\]. Clinical studies have demonstrated a high mortality rate among patients with carbapenem-resistant Enterobacteriaceae infection \[[@CIT0001]\]. An optimal antimicrobial regimen is important in the treatment of carbapenem-resistant Enterobacteriaceae infection. Tigecycline and colistin are considered as a last-resort treatment for these infections \[[@CIT0001]\].

In previous studies of carbapenem-resistant Enterobacteriaceae bloodstream infections \[[@CIT0004]\], an appropriate antimicrobial regimen was defined as at least 1 in vitro active agent according to breakpoints established by the Clinical and Laboratory Standards Institute (CLSI) \[[@CIT0015]\] or the European Committee on Antimicrobial Susceptibility Testing (EUCAST) \[[@CIT0016]\]. However, the CLSI did not issue interpretative criteria for tigecycline susceptibility. The EUCAST recommends tigecycline susceptibility breakpoints in Enterobacteriaceae of susceptible minimum inhibitory concentration (MIC) ≤1 mg/L and resistant MIC \>2 mg/L \[[@CIT0016]\]. In addition, most of the studies used the interpretative criteria from the US Food and Drug Administration (FDA) for tigecycline (susceptible, MIC ≤2 mg/L; intermediate, MIC = 4 mg/L; resistant, MIC \>4 mg/L) \[[@CIT0017]\]. Therefore, defining an appropriate therapy with tigecycline against Enterobacteriaceae is challenging. Moreover, the steady-state maximal serum concentrations of tigecycline (0.6 mg/L) \[[@CIT0018]\] were lower than the current breakpoints proposed by the EUCAST or FDA. However, the issue of low serum concentration had not been addressed in the above-mentioned studies \[[@CIT0004]\], and the efficacy of tigecycline in the treatment of bacteremia is also debated in the literature \[[@CIT0019]\].

In this multicenter study, we investigated the independent risk factors for mortality among patients with bloodstream infections caused by carbapenem-resistant *Klebsiella pneumoniae* and *Escherichia coli*. We proposed a new definition of appropriate antimicrobial therapy with tigecycline in these infections. We aimed to investigate the impact of different regimens of antimicrobial therapy, especially tigecycline, on mortality in patients who received appropriate therapy in these infections.

MATERIALS AND METHODS {#s1}
=====================

Study Setting and Patients {#s2}
--------------------------

Patients with at least 1 positive blood culture were defined as having bloodstream infections. Bloodstream infections caused by carbapenem-resistant *K pneumoniae* and *E coli* were identified from 16 hospitals (12 medical centers and 4 regional hospitals \[[Supplementary Data](#sup1){ref-type="supplementary-material"}\]) in Taiwan between January 1, 2012 and June 30, 2015. Carbapenem resistance was defined as nonsusceptibility to imipenem or meropenem (MIC ≥2 mg/L) based on the interpretative criteria from CLSI published in 2012 \[[@CIT0015]\]. Only the first episode of bloodstream infections was included for each patient. The clinical data were retrospectively collected, and patients aged \<20 years, polymicrobial infections, and those with incomplete medical records were excluded. Patients who did not receive at least 48 hours of at least 1 appropriate antibiotic were also excluded. The detailed information of appropriate therapy is described under the following section. The study protocol was approved by the institutional review board of each participating hospital.

Microbiologic Methods {#s3}
---------------------

Carbapenem-resistant *K pneumoniae* and *E coli* isolates were collected from blood culture in the microbiological laboratories of each participating hospitals. The isolates were sent to the National Health Research Institutes (Miaoli, Taiwan) and were stored at −70°C in 10% glycerol Luria-Bertani medium before analysis. Bacterial identification was performed by a VITEK 2 automated system (bioMérieux, Marcy l'Etoile, France). Minimum inhibitory concentrations were determined by broth microdilution (Sensititre; Trek Diagnostic Systems, Cleveland, OH) for all antibiotics except tigecycline. The MICs for tigecycline were determined using the Etest (bioMérieux) on Mueller-Hinton medium. The results were interpreted according to the breakpoints published by CLSI, except those for colistin and tigecycline. Colistin was interpreted according to breakpoints established by EUCAST, and tigecycline was interpreted according to breakpoints established by the FDA. Carbapenem-resistant *K pneumoniae* and *E coli* isolates were screened for carbapenemase genes, plasmid-borne AmpC-like genes, and extended-spectrum β-lactamases (ESBL) genes using polymerase chain reaction detection as described previously \[[@CIT0020]\]. Bacterial outer membrane proteins (OMPs) were isolated, and the OMP profiles (OmpK35 and OmpK36 for *K pneumoniae*, and OmpC and OmpF for *E coli*) were identified by sodium dodecyl sulfate polyacrylamide gel electrophoresis followed by coomassie blue staining (Bio-Rad). *Klebsiella pneumoniae* American Type Culture Collection (ATCC) 13883 and *E coli* ATCC25922 were used as the control strains \[[@CIT0024], [@CIT0025]\].

Definitions {#s4}
-----------

The probable source of bloodstream infections, including pneumonia, urinary tract infection, surgical site infection, intra-abdominal infection, catheter-related infection, or primary bacteremia, was determined on the basis of microbiological results and physicians' findings. The definition of healthcare- associated infection was described previously \[[@CIT0026]\]. Severity of illness at the time of onset of infection was assessed by the Acute Physiology and Chronic Health Evaluation II (APACHE II) score. Appropriate antimicrobial therapy, including carbapenems, in patients enrolled in this study was defined as treatment with at least 1 agent to which the isolate was susceptible in vitro according to EUCAST breakpoints \[[@CIT0016]\]. For tigecycline, target values of area under curve/MIC ≥6.96 have been reported to be predictive of clinical response \[[@CIT0027]\]. The steady-state maximal serum concentration of tigecycline was 0.6 mg/L \[[@CIT0028]\]. To achieve the target values with a standard dose (100-mg loading dose followed by 50 mg twice daily), \>90% probability of target attainment could be expected at tigecycline MIC ≤0.5 mg/L \[[@CIT0028]\]. Therefore, we defined appropriate antimicrobial therapy with tigecycline when the strains exhibited MIC ≤0.5 mg/L. Appropriate antimicrobial therapy with colistin was defined as an isolate being susceptible in vitro according to the EUCAST breakpoint (MIC ≤2 mg/L) \[[@CIT0016]\]. Antimicrobial therapy in these patients usually varied, making it hard to classify them to a specific regimen; therefore, patients were assigned to a regimen only if it was initiated during the first 5 days after the sampling of blood culture and maintained for at least 48 hours \[[@CIT0029]\]. Appropriate combination therapy was defined as 2 or more appropriate antibiotics administrated simultaneously for \>48 hours.

Predictors of Mortality and Treatment Regimens {#s5}
----------------------------------------------

The primary outcome was death within 14 days from the onset of bloodstream infection. Risk factors for mortality in patients with bloodstream infections due to carbapenem-resistant *K pneumoniae* and *E coli* were investigated by comparing clinical variables of survivor and nonsurvivor subgroups.

The therapeutic regimens for patients with carbapenem-resistant *K pneumoniae* and *E coli* bloodstream infections were selected at the discretion of the attending physicians. There was no standard hospital guideline for antimicrobial therapy in carbapenem-resistant *K pneumoniae* and *E coli* infections. The recommended total daily dose of colistin was usually 9 million IU given in 2 or 3 divided dosages, and for tigecycline the total daily dose was 100 administered in 2 divided dosages. Usual doses of carbapenems were used: 500 mg for imipenem every 6 hours, 500 mg for doripenem, and 1 gram for meropenem every 8 hours. Dosages were adjusted to creatinine clearance when indicated.

Statistical Analysis {#s6}
--------------------

Categorical variables were evaluated with the χ^2^ or 2-tailed Fisher's exact test. Continuous variables were compared with the Student *t* test (for normally distributed variables) or the Mann-Whitney *U* test (for nonnormally distributed variables). We used cox proportional regression model to identify independent predictors of mortality. All biologically plausible variables with *P* \< .20 in univariate testing were incorporated into the model using a backward approach. Hazard ratio (HR) and 95% confidence interval (CI) were calculated. Two-tailed tests were used to determine statistical significance and *P* \< .05 was considered significant. Sensitivity analysis was performed as well among patients who received monotherapy only. All statistical analyses were performed using SPSS, version 17 (SPSS Inc., Chicago, IL).

RESULTS {#s7}
=======

Characteristics of Patients With Carbapenem-Resistant *Klebsiella pneumoniae* and *Escherichia coli* Bloodstream Infections {#s8}
---------------------------------------------------------------------------------------------------------------------------

A total of 125 cases with bloodstream infections caused by carbapenem-resistant *K pneumoniae* and *E coli* were identified during the study period. Sixty-one cases were excluded because of polymicrobial infection (n = 39), mortality within 48 hours (n = 14), or inappropriate therapy (n = 8). Finally, 64 cases were analyzed in this study. *Klebsiella pneumoniae* accounted for the majority of infections (n = 50, 78.1%). The demographic and clinical characteristics of the patients are shown in [Table 1](#T1){ref-type="table"}. The ages of the patients ranged from 20 to 94 years, with a median age of 71 years, and 39 patients were male. The 14-day mortality rate was 31.3% and the overall in-hospital mortality rate was 53.1%.

###### 

Characteristics of Patients With Carbapenem-Resistant *Klebsiella pneumoniae* and *Escherichia coli* Bloodstream Infections^a^

  --------------------------------------------------------- ------------- ------------- --------------- -------
  Variables                                                 Total\        14-Day\       14-Day\         *P*
                                                            (n = 64)      Survivors\    Nonsurvivors\   
                                                                          (n = 44)      (n = 20)        

  Demographics                                                                                          

   Age, years, median (IQR)                                 71 (61--77)   72 (62--77)   67 (60--80)     .875

   Male sex                                                 39 (60.9)     26 (59.1)     13 (65.0)       .653

   Nosocomial-acquired infection                            62 (96.9)     42 (95.5)     20 (100)        1.000

   Healthcare-associated infection                          2 (3.1)       2 (4.5)       0 (0.0)         1.000

   ICU-acquired isolate                                     30 (46.9)     19 (43.2)     11 (55.0)       .380

   Previous hospitalization^b^                              32 (50)       20 (45.5)     12 (60.0)       .281

  Microbiology                                                                                          

   *K pneumoniae*                                           50 (78.1)     34 (77.3)     16 (80.0)       .807

   *E coli*                                                 14 (21.9)     10 (22.7)     4 (20.0)        .807

   Carbapenemase                                            17 (26.6)     12 (27.3)     5 (25.0)        .849

  Clinical Syndrome                                                                                     

   Pneumonia                                                19 (29.7)     11 (25.0)     8 (40.0)        .223

   Urinary tract infection                                  3 (4.7)       3 (6.8)       0 (0.0)         .546

   Intra-abdominal infection                                19 (29.7)     11 (25.0)     8 (40.0)        .223

   Catheter-associated infection                            5 (7.8)       3 (6.8)       2 (10.0)        .644

   Skin and soft tissue infection                           3 (4.7)       1 (2.3)       2 (10.0)        .214

   Primary bacteremia                                       15 (23.4)     15 (34.1)     0 (0.0)         .003

  Comorbidities                                                                                         

   Diabetes mellitus                                        21 (32.8)     14 (31.8)     7 (35.0)        .802

   Chronic obstructive pulmonary disease                    6 (9.4)       4 (9.1)       2 (10.0)        1.000

   Chronic respiratory failure with mechanical ventilator   17 (26.6)     9 (20.5)      8 (40.0)        .101

   Congestive heart failure                                 12 (18.8)     10 (22.7)     2 (10.0)        .227

   Cerebrovascular disease                                  14 (21.9)     10 (22.7)     4 (20.0)        .807

   Chronic kidney disease^c^                                20 (31.3)     13 (30.2)     7 (36.8)        .608

   Liver cirrhosis                                          7 (10.9)      4 (9.1)       3 (15.0)        .668

   Malignancy                                               26 (40.6)     14 (31.8)     12 (60.0)       .033

   Immunocompromised state^d^                               12 (18.8)     8 (18.2)      4 (20.0)        .863

   Previous surgery^e^                                      24 (37.5)     17 (38.6)     7 (35.0)        .781

   Charlson Comorbidity Index, median (IQR)                 4 (2--7)      4 (2--7)      6 (2--8)        .173

  Invasive Procedures 7 Days Preceding Onset of infection                                               

   Indwelled central venous catheter                        35 (54.7)     26 (59.1)     9 (45.0)        .294

   Indwelled urinary catheter                               33 (51.6)     23 (52.3)     10 (50.0)       .866

   Surgical drainage                                        13 (20.3)     7 (15.9)      6 (30.0)        .194

   Mechanically ventilated                                  29 (45.3)     18 (40.9)     11 (55.0)       .294

   Renal replacement therapy                                16 (25.0)     10 (22.7)     6 (30.0)        .533

  Severity of Illness                                                                                   

   Septic shock                                             13 (20.3)     7 (15.9)      6 (30.0)        .194

   APACHE II score, median (IQR)                            25 (17--30)   23 (17--28)   28 (18--34)     .048

  Therapy                                                                                               

   Monotherapy, No. (%)                                     55 (85.9)     38 (86.4)     17 (85.0)       .884

   Colistin monotherapy                                     21 (32.8)     9 (20.5)      12 (60.0)       .002

   Tigecycline monotherapy                                  11 (17.2)     9 (20.5)      2 (10.0)        .304

   Other monotherapy                                        23 (35.9)     20 (45.5)     3 (15.0)        .019

   Combination therapy, No. (%)                             9 (14.1)      6 (13.6)      3 (15.0)        .884
  --------------------------------------------------------- ------------- ------------- --------------- -------

Abbreviations: APACHE, Acute Physiology and Chronic Health Evaluation; HIV, human immunodeficiency virus; ICU, intensive care unit; IQR, interquartile range.

^a^Data are expressed as number (%) unless specified otherwise.

^b^Within 3 months preceding onset of infection.

^c^Chronic kidney disease stage 4 and stage 5.

^d^Use of steroid dose equivalent to ≥20 mg of prednisolone or immunosuppressants 30 days preceding onset of infection, patients as transplantation recipient, or patients with HIV infection.

^e^Within 30 days preceding onset of infection.

Microbiological Characteristics of Carbapenem-Resistant *Klebsiella pneumoniae* and *Escherichia coli* Isolates {#s9}
---------------------------------------------------------------------------------------------------------------

Of the 64 isolates, 17 (26.6%) had genes that encoded carbapenemases, including *K pneumoniae* carbapenemase (KPC)-2 (n = 11), imipenemase (IMP)-8 (n = 1), Verona integron-encoded metallo-β-lactamase (VIM)-1 (n = 2), oxacillinase (OXA)-48 (n = 1), New Delhi metallo-β-lactamase (NDM)-1 (n = 1), and 1 with both KPC-2 and IMP-8. Almost all the carbapenemase-producing strains were *K pneumoniae*, and only 1 *E coli* with carbapenemase (NDM-1) was identified. Other noncarbapenemase-producing strains had genes that encoded plasmid-borne AmpC/ESBL and the loss of outer membrane porins ([Supplementary Data](#sup1){ref-type="supplementary-material"}). All of the strains were resistant to ceftriaxone or ceftazidime. The MIC of tigecycline was ≥0.5 mg/L for 46 (71.9%), 1--2 mg/L for 16 (25%), and \>2 mg/L for 2 (3.1%). The MIC of imipenem or meropenem was ≥8 mg/L for 48 (75%) isolates and 4 mg/L for 9 isolates (6.3%).

Risk Factors for 14-Day Mortality {#s10}
---------------------------------

[Table 2](#T2){ref-type="table"} showed the risk factors for 14-day mortality among patients with carbapenem-resistant *K pneumoniae* and *E coli* bloodstream infections. Chronic respiratory failure with mechanical ventilator, malignancy, Charlson Comorbidity Index, surgical drain, septic shock, APACHE II score, colistin monotherapy, and monotherapy other than colistin or tigecycline were incorporated into multivariate cox regression. Combination therapy was not associated with 14-day survival in the univariate analysis. In multivariate analysis, Charlson Comorbidity Index (HR, 1.21; 95% CI, 1.03--1.42; *P* = .022) and colistin monotherapy (HR, 5.57; 95% CI, 2.13--14.61; *P* \< .001) were independently associated with 14-day mortality.

###### 

Cox Proportional Hazards Regression Analysis of Predictors Associated With 14-Day Mortality of Patients With Carbapenem-Resistant *Klebsiella pneumoniae* and *Escherichia coli* Bloodstream Infections^a^

  -------------------------------------------------------- --------------------- ------ ------------------------ --------
  Variables                                                Univariate Analysis          Multivariable Analysis   

                                                           HR\                   *P*    HR\                      *P*
                                                           (95% CI)                     (95% CI)                 

  Chronic respiratory failure with mechanical ventilator   2.14 (0.87--5.24)     .096                            

  Malignancy                                               2.29 (0.94--5.62)     .069                            

  Charlson Comorbidity Index                               1.11 (0.96--1.29)     .147   1.21 (1.03--1.42)        .022

  Surgical drain                                           1.93 (0.74--5.02)     .180                            

  Septic shock                                             2.08 (0.80--5.42)     .134                            

  APACHE II score                                          1.07 (1.01--1.13)     .024                            

  Colistin monotherapy                                     4.05 (1.65--9.96)     .002   5.57 (2.13--14.61)       \<.001

  Other monotherapy                                        0.25 (0.07--0.86)     .028                            
  -------------------------------------------------------- --------------------- ------ ------------------------ --------

Abbreviations: APACHE, Acute Physiology and Chronic Health Evaluation; CI, confidence interval; HR, hazard ratio; ICU, intensive care unit.

^a^All biologically relevant variables with *P* \< .20 in the univariate cox proportional regression analysis were included in the multivariate analysis.

We further evaluated the risk factors for 28-day mortality among the 64 patients. The result was similar to that in the analysis for 14-day mortality. Charlson Comorbidity Index (HR, 1.21; 95% CI, 1.04--1.40; *P* = .011) and colistin monotherapy (HR, 5.31; 95% CI, 2.24--12.6; *P* \< .001) were still independently associated with 28-day mortality.

Monotherapy With Tigecycline in Carbapenem-Resistant *Klebsiella pneumoniae* and *Escherichia* Bloodstream Infections {#s11}
---------------------------------------------------------------------------------------------------------------------

[Table 3](#T3){ref-type="table"} showed detailed antimicrobial regimens among the 64 patients. We compared the 14-day mortality among the 64 patients who received different antimicrobial regimen ([Figure 1](#F1){ref-type="fig"}). Most of the cases (n = 55) in the current study received monotherapy. Colistin monotherapy was associated with a higher mortality than that in tigecycline monotherapy (57.1% versus 18.2%, *P* = .035) and monotherapy other than colistin or tigecycline (57.1% versus 13.0%, *P* = .002). No mortality difference was noted among other regimen comparison. We defined appropriate therapy with tigecycline when the strains exhibited MIC ≤0.5 mg/L in the current study. We further compared the 11 patients with tigecycline monotherapy and those with other monotherapy (n = 44). The clinical characteristics and 14-day mortality were not different significantly between these 2 groups ([Table 4](#T4){ref-type="table"}). [Figure 2](#F2){ref-type="fig"} showed no significant difference in mortality between the 2 groups in the survival curve (log-rank test, *P* = .392). Among the 55 patients with monotherapy, the 14-day mortality was 30.9% (n = 17). Tigecycline was not associated with survival benefit independently in the multivariate cox regression model (data not shown).

###### 

Detailed Antimicrobial Therapy of Patients With Carbapenem-Resistant *Klebsiella pneumoniae* and *Escherichia coli* Bloodstream Infections^a^

  ----------------------------------------- ----------- -------------------------
  Antimicrobial Regimens                    n (%)       14-Day Mortality, n (%)
  Monotherapy                               55          17/55 (30.9)
  Colistin                                  21 (38.2)   12/21 (57.1)
  Tigecycline                               11 (20.0)   2/11 (18.2)
  Aminoglycoside^b^                         7 (12.7)    0/7 (0)
  Cefepime                                  6 (10.9)    1/6 (16.7)
  Carbapenem^c^                             5 (9.1)     1/5 (20.0)
  Fluoroquinolone^d^                        4 (7.3)     1/4 (25.0)
  Piperacillin + tazobactam                 1 (1.8)     0/1 (0)
  Combination therapy                       9           3/9 (33.3)
  Aminoglycoside+ carbapenem                1 (11.1)    0/1 (0)
  Aminoglycoside + tigecycline              1 (11.1)    0/1 (0)
  Colistin + carbapenem                     2 (22.2)    1/2 (50)
  Colistin + tigecycline                    2 (22.2)    1/2 (50)
  Colistin + tigecycline + carbapenem       1 (11.1)    0/1 (0)
  Colistin + tigecycline + aminoglycoside   1 (11.1)    0/1 (0)
  Tigecycline + carbapenem                  1 (11.1)    1/1 (100)
  ----------------------------------------- ----------- -------------------------

^a^Data are presented as number (%) unless specified otherwise.

^b^Amikacin or gentamicin.

^c^Group 2 carbapenem (imipenem, meropenem, or doripenem).

^d^Ciprofloxacin or levofloxacin.

![The 14-day mortality among the 64 patients who received different antimicrobial regimen. The mortality of colistin monotherapy was significantly higher than that in the other regimen.](ofidis_ofy336_f0001){#F1}

###### 

Comparison Between Patients Treated With Tigecycline Monotherapy and Non-Tigecycline Monotherapy^a^

  --------------------------------------------------------- -------------------------- ------------------------------ -------
  Variables                                                 Tigecycline Monotherapy\   Non-Tigecycline Monotherapy\   *P*
                                                            (n = 11)                   (n = 44)                       

  Demographics                                                                                                        

   Age, years, median (IQR)                                 67 (56--77)                72 (63--77.75)                 .335

   Male sex                                                 8 (72.7)                   26 (59.1)                      .405

   Nosocomial-acquired infection                            11 (100)                   43 (97.7)                      1.000

   Healthcare-associated infection                          0 (0.0)                    1 (2.3)                        1.000

   ICU-acquired isolate                                     4 (36.4)                   23 (52.3)                      .345

   Previous hospitalization^b^                              4 (36.4)                   24 (54.5)                      .281

  Microbiology                                                                                                        

   *Klebsiella pneumoniae*                                  9 (81.8)                   35 (79.5)                      .866

   *Escherichia coli*                                       2 (18.2)                   9 (20.5)                       .866

   Carbapenemase-producing strains                          3 (27.3)                   13 (29.5)                      .882

  Clinical Syndrome                                                                                                   

   Pneumonia                                                5 (45.5)                   11 (25.0)                      .182

   Urinary tract infection                                  0 (0.0)                    2 (4.5)                        1.000

   Intra-abdominal infection                                3 (27.3)                   13 (29.5)                      .882

   Catheter-associated infection                            0 (0.0)                    5 (11.4)                       .571

   Skin and soft tissue infection                           0 (0.0)                    2 (4.5)                        1.000

   Primary bacteremia                                       3 (27.3)                   11 (25.0)                      .877

  Comorbidities                                                                                                       

   Diabetes mellitus                                        3 (27.3)                   13 (29.5)                      .882

   Chronic obstructive pulmonary disease                    2 (18.2)                   3 (6.8)                        .259

   Chronic respiratory failure with mechanical ventilator   2 (18.2)                   11 (25.0)                      .634

   Congestive heart failure                                 2 (18.2)                   7 (15.9)                       .855

   Cerebrovascular disease                                  5 (45.5)                   5 (11.4)                       .009

   Chronic kidney disease^c^                                4 (36.4)                   13 (29.5)                      .662

   Liver cirrhosis                                          1 (9.1)                    6 (13.6)                       .686

   Malignancy                                               3 (27.3)                   19 (43.2)                      .335

   Immunocompromised state^d^                               3 (27.3)                   8 (18.2)                       .500

   Previous surgery^e^                                      4 (36.4)                   19 (43.2)                      .682

   Charlson Comorbidity Index, median (IQR)                 6 (3--12)                  7 (3--9)                       .135

  Invasive Procedures 7 Days Preceding Onset of Infection                                                             

   Indwelled central venous catheter                        6 (54.5)                   24 (54.5)                      1.000

   Indwelled urinary catheter                               6 (54.5)                   23 (52.3)                      .893

   Surgical drainage                                        3 (27.3)                   9 (20.5)                       .624

   Mechanically ventilated                                  3 (27.3)                   22 (50.0)                      .176

   Renal replacement therapy                                4 (36.4)                   9 (20.5)                       .267

  Severity of Illness                                                                                                 

   Septic shock                                             2 (18.2)                   8 (18.2)                       1.000

   APACHE II score, median (IQR)                            22 (17--30)                25.5 (16.25--28.75)            .758

   14-day mortality                                         2 (18.2)                   15 (34.1)                      .307
  --------------------------------------------------------- -------------------------- ------------------------------ -------

Abbreviations: APACHE, Acute Physiology and Chronic Health Evaluation; HIV, human immunodeficiency virus; ICU, intensive care unit; IQR, interquartile range.

^a^Data are expressed as number (%) unless specified otherwise.

^b^Within 3 months preceding onset of infection.

^c^Chronic kidney disease stage 4 and stage 5.

^d^Use of steroid dose equivalent to ≥20 mg of prednisolone or immunosuppressants 30 days preceding onset of infection, patients as transplantation recipient, or patients with HIV infection.

^e^Within 30 days preceding onset of infection.

![Kaplan-Meier survival curve of patients treated with monotherapy. The survival of tigecycline monotherapy (solid line) was not significantly different from that in non-tigecycline monotherapy (dotted line) (log-rank test; *P* = .392).](ofidis_ofy336_f0002){#F2}

DISCUSSION {#s12}
==========

In this study, we investigated patients with bloodstream infections caused by carbapenem-resistant *K pnuemoniae* and *E coli* who received appropriate antimicrobial therapy. We proposed a new definition of appropriate antimicrobial therapy with tigecycline. We found that colistin monotherapy and Charlson Comorbidity Index were the independent predictors for 14-day mortality. Tigecycline monotherapy was not associated with a higher mortality among patients with monotherapy.

In Taiwan, the major mechanism for carbapenem-resistant Enterobacteriaceae was not mediated by carbapenemase until 2015 \[[@CIT0020]\]. We included both carbapenemase-producing and noncarbapenemase-producing strains in this study, aiming to generalize our findings in the real-life practice. Many microbiology laboratories do not perform the molecular detection of carbapenemase routinely, and the physicians usually treat these infections according to the MICs interpreted by the CLSI or EUCAST. Therefore, the current study is able to help physicians manage bloodstream infections caused by carbapenem-resistant *K pnuemoniae* and *E coli* according to the MICs, regardless of the mechanisms of carbapenem resistance.

Most studies regarding treatment for carbapenem-resistant Enterobacteriaceae bloodstream infections \[[@CIT0004], [@CIT0012]\] defined appropriate use of tigecycline according to the FDA criteria (susceptibile, MIC ≤2 mg/L). Tumbarello et al \[[@CIT0011]\] used EUCAST criteria to define the appropriate use of tigecycline (susceptibile, MIC ≤1 mg/L) in KPC-producing *K pneumoniae* bacteremia. We defined tigecycline use in bloodstream infection as appropriate only when the isolates exhibited MIC ≤0.5 mg/L, based on previous pharmacodynamics study \[[@CIT0027], [@CIT0028]\]. With tigecycline MIC ≤0.5 mg/L, a \>90% probability of target attainment could be expected, and the cumulative fraction of response was 82.0%, based on previous pharmacokinetics and EUCAST wild-type MIC distributions of *K pneumoniae* \[[@CIT0028]\]. Tigecycline is considered as a potent therapeutic option for carbapenem-resistant Enterobacteriaceae infections \[[@CIT0030]\], but the efficacy of tigecycline cannot be clearly defined because a suitable definition of appropriate therapy is lacking. One recent meta-analysis showed that the efficacy of tigecycline in treating carbapenem-resistant Enterobacteriaceae infections is similar to that of other antibiotics \[[@CIT0031]\], but the issue of suboptimal concentrations of tigecycline was still not discussed \[[@CIT0031]\]. In the literature, cases treated with tigecycline monotherapy in bloodstream infections due to carbapenem-resistant *K pneumoniae* are limited. The current study first adopted a new definition of appropriate tigecycline in bloodstream infections caused by carbapenem-resistant *K pneumoniae* and *E coli* taking into account the low serum level of tigecycline. Our study found that tigecycline monotherapy was not associated with 14-day mortality if the strains exhibited MIC ≤0.5 mg/L. Our results provided some insight into tigecycline treatment in carbapenem-resistant Enterobacteriaceae bacteraemia and might initiate additional prospective studies to solidify the findings.

In this study, we found that colistin monotherapy was independently associated with poor outcome. We cannot demonstrate whether colistin-based combination therapy is better, because of the limited number of cases with combination therapy in our analysis. One recent study conducted by de Oliveira et al \[[@CIT0032]\] demonstrated that polymyxins was associated with a higher risk of mortality in KPC-producing Enterobacteriaceae infections, and dosage was the major concern. The dosing guidance of cilistin is necessary because of the extensive interpatient variability in pharmacokinetics \[[@CIT0033]\]. One recent study proposed clinician-friendly dosing algorithms and suggested that monotherapy with intravenous colistin may be suboptimal \[[@CIT0033]\]. In our study, the difficulty in selecting an optimal dose in bloodstream infections may be the reason for the low efficacy of colistin. We also identified that the Charlson Comorbidity Index influenced the outcome, which emphasized the role of host factors in combating carbapenem-resistant bacteria.

One major limitation of this study was that clinical data were obtained retrospectively from medical records. Several missing variables, such as source control, might have had potential effects on outcome. An additional limitation was the limited number of cases, especially patients with combination therapy, which precluded further analysis. Finally, the limited cases treated with tigecycline monotherapy was another limitation of this analysis. Nevertheless, our study provided the first new definition of appropriate tigecycline monotherapy in these serious infections.

CONCLUSIONS {#s13}
===========

In conclusion, we used a new definition of appropriate antimicrobial therapy with tigecycline in the treatment of bloodstream infections caused by carbapenem-resistant *K pneumoniae* and *E coli*. Our findings suggested that tigecycline monotherapy therapy was an appropriate choice if the strains exhibited MIC ≤0.5 mg/L, and colistin monotherapy is not suitable. In the era of limited new drugs, our findings can initiate additional clinical studies regarding the efficacy of tigecycline in carbapenem-resistant Enterobacteriaceae infections.

Supplementary Data {#s14}
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Supplementary materials are available at *Open Forum Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.
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